Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Merck-Cardiome Heart Drug Gets Positive EU Review(2)

By Pharmaceutical Processing | June 25, 2010

NEW YORK (AP) — A drug candidate used to restore a steady heartbeat received a recommendation for approval in Europe, according to Merck and Co. and Cardiome Pharma Corp.

The companies said Friday the Committee for Medicinal Products for Human Use said Brinavess should be approved as a treatment for recent onset atrial fibrillation in adults. Atrial fibrillation is a condition that causes the upper chambers of the heart to beat rapidly and ineffectively.

The recommendation improves the chances that European Union regulators will approve Brinavess for sale in the 27 EU countries, along with Norway and Iceland. Regulators will complete a review of the drug later this year.

Brinavess, or vernakalant, is delivered by infusion. Merck and Cardiome are also working on an oral version of the drug. The companies have also applied for U.S. approval of the infusion form of the drug.

A competing drug, Sanofi-Aventis’ Multaq, was approved in 2009.

Separately, Merck said the committee made a decision on its drug candidate Sycrest. The committee recommended that Sycrest be approved as a treatment for treating moderate to severe episodes associated with bipolar disorder in adults. However the committee did not recommend approval of Sycrest, or asenapine, as a treatment for schizophrenia.

Merck is headquartered in Whitehouse Station, N.J., and Cardiome is based in Vancouver, British Columbia.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE